As of January 1, 2013

ZIOPTAN is now a Tier 2 PREFERRED BRAND on the CVS Caremark Commercial formulary1, 2, a


ZIOPTAN—Lowest branded co-pay through one of the nation’s largest pharmacy benefit managers.1–3

Lumigan is no longer listed as a preferred product on the CVS Caremark Commercial Prescribing Guide and Performance Drug List and, therefore, may not be covered or may require a higher out-of-pocket expense for certain patients.1, 4

Lower co-pay costs alone do not necessarily reflect a cost advantage in the outcome of the condition treated, because there are other variables that affect relative costs. Formulary status alone does not imply a comparison of safety, efficacy, or dosage regimens of these products.1, 2

Current formulary status is believed to be accurate, but cannot be guaranteed.1

Formulary status on national formulary may not reflect formulary status for individual plans or specific benefit designs. Additionally, inclusion on the CVS Caremark Commercial formulary does not mean that ZIOPTAN is, or will be, included on any CVS Caremark Medicare Part D formulary.1

Lumigan is a trademark of its respective owner. aCVS Caremark Commercial formulary=CVS Caremark’s Prescribing Guide and Performance Drug List. References: 1. CVS Caremark Primary/Preferred Drug List. Caremark, LLC; January 2013. 2. CVS Caremark. Formulary Development and Management at CVS Caremark. Caremark; 2012. 3. CVS Caremark corporate profile. CVS Web site. Accessed November 28, 2012. 4. CVS Caremark Primary/Preferred Drug List. Caremark, LLC; October 2012.

Select Important Safety Information

ZIOPTAN has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as ZIOPTAN is administered. After discontinuation of ZIOPTAN, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. The long-term effects of increased pigmentation are not known. Iris color change may not be noticeable for several months to years. While treatment with ZIOPTAN can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.

ZIOPTAN may gradually change eyelashes and vellus hair in the treated eye. These changes include increased length, color, thickness, shape, and number of lashes. Eyelash changes are usually reversible on discontinuation of treatment.

ZIOPTAN should be used with caution in patients with active intraocular inflammation (e.g., iritis/uveitis) because the inflammation may be exacerbated.

Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin F2α analogs. ZIOPTAN should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

In clinical trials of patients receiving either preservative-containing or preservative-free ZIOPTAN, the most common pooled adverse reaction observed was conjunctival hyperemia, which was reported in a range of 4% to 20% of patients.

Before prescribing ZIOPTAN, please read the Prescribing Information.